After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Sanofi's Consumer Healthcare division, Opella, announced that the U.S. Food and Drug Administration has lifted a clinical hold on its ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Sanofi says the deal announced today will make it the world's number one consumer health company, with expected revenues of around €5.1 billion in 2015 ($5.61 billion) and a global market share ...

Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...

Fluoride helps prevent cavities when applied topically to the teeth, but when ingested can pose significant risks, even kill ...

Procter & Gamble and Colgate-Palmolive are among the defendants in six new lawsuits because of products that contain fluoride ...

Procter & Gamble, Colgate, Perrigo and Sanofi ... mislead consumers into believing these products are harmless to young children." The relationship between fluoride and human health has long ...

“Both companies are ‘houses of brands’, in other words a collection of well-diversified luxury businesses serving multiple ...

Banks are pitching around €1 billion ($1.05 billion) in debt packages to back a potential buyout of Karo Healthcare, according to people familiar with the matter.

The French pharmaceutical company Sanofi SA has received mandatory offers to acquire the Consumer Health division from private equity firms Clayton Dubilier & Rice and PAI Partners. This is reported ...